{"drugs":["Siltuximab","Sylvant"],"mono":{"0":{"id":"930940-s-0","title":"Generic Names","mono":"Siltuximab"},"1":{"id":"930940-s-1","title":"Dosing and Indications","sub":[{"id":"930940-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Multicentric Castleman's disease, In patients known to be HIV-negative and human herpesvirus-8-negative:<\/b> initial, consider delay of treatment, but do not reduce dose, for absolute neutrophil count (ANC) less than 1 x 10(9)\/L, platelet count less than 75 x 10(9)\/L, Hb 17 g\/dL or greater<\/li><li><b>Multicentric Castleman's disease, In patients known to be HIV-negative and human herpesvirus-8-negative:<\/b> 11 mg\/kg IV infusion over 1 hour every 3 weeks until treatment failure; consider delay of retreatment, but do not reduce dose, for ANC less than 1 x 10(9)\/L, platelet count less than 50 x 10(9)\/L, Hb 17 g\/dL or greater<\/li><\/ul>"},{"id":"930940-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"930940-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment (CrCl 25 mL\/min or greater):<\/b> no initial dose adjustment necessary<\/li><li><b>hepatic impairment (mild to moderate; Child-Pugh Class A and B):<\/b> no initial dose adjustment necessary<\/li><\/ul>"},{"id":"930940-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Multicentric Castleman's disease, In patients known to be HIV-negative and human herpesvirus-8-negative<br\/>"}]},"3":{"id":"930940-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930940-s-3-9","title":"Contraindications","mono":"severe hypersensitivity to siltuximab or any of the product excipients <br\/>"},{"id":"930940-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- gastrointestinal (GI) perforation has been reported; use with caution in at risk patients and promptly evaluate if symptoms suggest GI perforation<\/li><li>Immunologic:<\/li><li>-- infections may occur; use not recommended if severe; monitoring recommended<\/li><li>Other:<\/li><li>-- infusion related reactions and hypersensitivity (eg, anaphylaxis) may occur; interrupt the infusion for mild to moderate infusion reactions and consider medications; depending on the severity of the reaction, may resume therapy with a reduced infusion rate after resolution of symptoms<\/li><li>Concomitant Use:<\/li><li>-- use not recommended with live virus vaccines<\/li><\/ul>"},{"id":"930940-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930940-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930940-s-4","title":"Drug Interactions","sub":{"1":{"id":"930940-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Adenovirus Vaccine Type 4, Live (theoretical)<\/li><li>Adenovirus Vaccine Type 7, Live (theoretical)<\/li><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Alprazolam (theoretical)<\/li><li>Aminophylline (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amlodipine (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atorvastatin (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Brinzolamide (theoretical)<\/li><li>Bromocriptine (theoretical)<\/li><li>Budesonide (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Buspirone (theoretical)<\/li><li>Cabazitaxel (theoretical)<\/li><li>Cabozantinib (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclophosphamide (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darifenacin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Docetaxel (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Dutasteride (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Estradiol (theoretical)<\/li><li>Ethinyl Estradiol (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Influenza Virus Vaccine, Live (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Letrozole (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Levonorgestrel (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Losartan (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Macitentan (theoretical)<\/li><li>Maraviroc (theoretical)<\/li><li>Measles Virus Vaccine, Live (theoretical)<\/li><li>Medroxyprogesterone (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Midazolam (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mumps Virus Vaccine, Live (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nifedipine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nimodipine (theoretical)<\/li><li>Nisoldipine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Ospemifene (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Poliovirus Vaccine, Live (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Roflumilast (theoretical)<\/li><li>Rotavirus Vaccine, Live (theoretical)<\/li><li>Rubella Virus Vaccine, Live (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sildenafil (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Simvastatin (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Smallpox Vaccine (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Triamcinolone (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Typhoid Vaccine (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Varicella Virus Vaccine (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Yellow Fever Vaccine (theoretical)<\/li><li>Zaleplon (theoretical)<\/li><li>Zileuton (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zolpidem (theoretical)<\/li><\/ul>"}}},"5":{"id":"930940-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema (26% (all grades); 8% (grade 3 or 4))<\/li><li><b>Dermatologic:<\/b>Lower respiratory tract infection (8%), Rash (28%), Upper respiratory infection (26% to 63%)<\/li><li><b>Endocrine metabolic:<\/b>Hypertriglyceridemia (8%), Hyperuricemia (11% (all grades); 2% (grade 3 or 4)), Weight increased (19% (all grades); 2% (grade 3 or 4))<\/li><li><b>Gastrointestinal:<\/b>Constipation (8%), Diarrhea (32% (longterm exposure)), Pain, oropharyngeal (8%)<\/li><li><b>Hematologic:<\/b>Thrombocytopenia (9% (all grades); 4% (grade 3 or 4))<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (21% (longterm exposure))<\/li><li><b>Neurologic:<\/b>Headache (8%)<\/li><li><b>Renal:<\/b>Renal impairment (8%)<\/li><li><b>Respiratory:<\/b>Rash (28% (all grades); 2% (grade 3 or 4))<\/li><li><b>Other:<\/b>Fatigue (21% (longterm exposure)), Pain, In extremities (21% (longterm exposure))<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastrointestinal perforation<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Infectious disease<\/li><li><b>Other:<\/b>Infusion reaction (4.8%)<\/li><\/ul>"},"6":{"id":"930940-s-6","title":"Drug Name Info","sub":{"0":{"id":"930940-s-6-17","title":"US Trade Names","mono":"Sylvant<br\/>"},"2":{"id":"930940-s-6-19","title":"Class","mono":"Monoclonal Antibody<br\/>"},"3":{"id":"930940-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930940-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930940-s-7","title":"Mechanism Of Action","mono":"Siltuximab is a human-mouse chimeric monoclonal antibody that binds soluble and membrane-bound interleukin-6 (IL-6). IL-6 can induce immunoglobulin secretion, and its overproduction is associated with systemic effects in patients with multicentric Castleman's disease.<br\/>"},"8":{"id":"930940-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930940-s-8-24","title":"Distribution","mono":"Vd: 4.5 L <br\/>"},"3":{"id":"930940-s-8-26","title":"Excretion","mono":"Total body clearance: 0.23 L\/day <br\/>"},"4":{"id":"930940-s-8-27","title":"Elimination Half Life","mono":"20.6 days <br\/>"}}},"9":{"id":"930940-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>allow vials to come to room temperature over approximately 30 minutes<\/li><li>use a 21-gauge, 1.5-inch needle for preparation<\/li><li>reconstitute to 20 mg\/mL with sterile water for injection (SWFI) by adding 5.2 mL to 100-mg vial or 20 mL to 400-mg vial<\/li><li>allow powder to completely dissolve without vigorous shaking or swirling; dissolution should occur within 60 minutes<\/li><li>add reconstituted solution to infusion bag within 2 hours and complete infusion within 4 hours of adding drug to infusion bag<\/li><li>250-mL infusion bag must contain D5W and be made of polyolefin (PO) or polyvinyl chloride (PVC) with DEHP<\/li><li>slowly add reconstituted solution to D5W to create a final volume of 250 mL and gently invert bag to mix<\/li><li>infuse over 1 hour through PVC with DEHP- or polyurethane-lined administration sets containing a 0.2-micron inline filter<\/li><li>do not infuse in the same IV line with other agents<\/li><li>for mild to moderate infusion reactions, interrupt the infusion and restart at lower infusion rate; consider antihistamines, acetaminophen, and corticosteroids; discontinue if interventions are unsuccessful.<\/li><li>for severe infusion or allergic reactions, anaphylaxis, or cytokine release syndromes, permanently discontinue and do not restart treatment<\/li><li>discard any unused portion of the drug<\/li><\/ul>"},"10":{"id":"930940-s-10","title":"Monitoring","mono":"<ul><li>tumor response and complete resolution or stabilization of multicentric Castleman's disease symptoms is indicative of efficacy<\/li><li>prior to the first dose: absolute neutrophil count is 1 x 10(9)\/L or greater, the platelet count is 75 x 10(9)\/L or greater, and the hemoglobin is less than 17 g\/dL<\/li><li>prior to retreatment: absolute neutrophil count is 1 x 10(9)\/L or greater, the platelet count is 50 x 10(9)\/L or greater, and the hemoglobin is less than 17 g\/dL<\/li><li>infection; during therapy<\/li><\/ul>"},"11":{"id":"930940-s-11","title":"How Supplied","mono":"<b>Sylvant<\/b><br\/>Intravenous Powder for Solution: 100 MG, 400 MG<br\/>"},"13":{"id":"930940-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that live vaccines are not to be taken during therapy.<\/li><li>Counsel patients of childbearing to avoid pregnancy during treatment and for 3 months after discontinuation.<\/li><li>Side effects may include rash, itching, respiratory tract infection, edema, constipation, or headache.<\/li><li>Instruct patient to report symptoms of infection.<\/li><li>Tell patient to report symptoms of allergic reaction (eg, difficulty breathing, chest tightness, wheezing, dizziness) during administration.<\/li><li>Counsel patient to report any new or worsening medical conditions during therapy.<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs.).<\/li><\/ul>"}}}